Free Trial

Johnson & Johnson (NYSE:JNJ) Reaches New 1-Year High - Here's Why

Johnson & Johnson logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Johnson & Johnson hit a 52-week high, trading as high as $289.30 on Monday, up from its previous close of $285.75.
  • The company’s latest quarter slightly beat expectations, with adjusted earnings of $2.59 per share and revenue of $25.40 billion, up 5.9% year over year. J&J also agreed to acquire Ollin Biosciences for $2.2 billion, adding potential eye-disease treatments to its pipeline.
  • Analysts rate the stock a “Moderate Buy”, with a consensus price target of $275.92—below its recent trading price. J&J announced a quarterly dividend of $1.34 per share, equivalent to a 1.9% yield.
  • Five stocks to consider instead of Johnson & Johnson.

Johnson & Johnson (NYSE:JNJ - Get Free Report)'s stock price reached a new 52-week high during trading on Monday. The company traded as high as $289.30 and last traded at $289.4330, with a volume of 33,648 shares. The stock had previously closed at $285.75.

Trending Headlines about Johnson & Johnson

Investors following JNJ have been watching these headlines:

  • Positive Sentiment: J&J agreed to acquire clinical-stage Ollin Biosciences, which is developing treatments for serious eye diseases. The purchase could strengthen its ophthalmology business and add future drug candidates, although clinical-stage assets carry development risk. The latest report puts the agreed deal at $2.2 billion; earlier reports described talks involving up to $3.4 billion. Johnson & Johnson to Buy Ollin Biosciences for $2.2 Billion
  • Neutral Sentiment: ETFs recorded $72.5 million in net J&J sales on Thursday. Another report said State Street’s health-care ETF sold J&J shares as part of a broader portfolio reduction, so the activity may reflect fund rebalancing rather than a company-specific change in outlook. ETFs Are Net Sellers of Johnson & Johnson
  • Negative Sentiment: Executive Vice President Elizabeth Forminard sold 13,072 shares for about $3.72 million, reducing her reported stake by 43.48%. Insider sales can weigh on sentiment, though a single transaction does not establish a change in the company’s fundamentals. Johnson & Johnson EVP Sells 13,072 Shares

Wall Street Analyst Weigh In

A number of research firms have issued reports on JNJ. JPMorgan Chase & Co. raised their target price on Johnson & Johnson from $270.00 to $285.00 and gave the stock a "neutral" rating in a research report on Tuesday, September 29th. Erste Group Bank downgraded Johnson & Johnson from a "buy" rating to a "hold" rating in a research note on Wednesday, October 21st. Guggenheim reissued a "buy" rating and issued a $287.00 price objective on shares of Johnson & Johnson in a report on Wednesday, October 7th. Weiss Ratings cut Johnson & Johnson from a "buy (b+)" rating to a "buy (b-)" rating in a research note on Friday, October 23rd. Finally, Wells Fargo & Company upped their price objective on shares of Johnson & Johnson from $275.00 to $287.00 and gave the company an "overweight" rating in a report on Friday, October 16th. One analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and eight have assigned a Hold rating to the company's stock. Based on data from MarketBeat, Johnson & Johnson has an average rating of "Moderate Buy" and a consensus price target of $275.92.

Read Our Latest Stock Report on Johnson & Johnson

Johnson & Johnson Price Performance

The business has a fifty day moving average of $266.97 and a 200-day moving average of $249.85. The firm has a market cap of $691.27 billion, a PE ratio of 43.46, a PEG ratio of 2.82 and a beta of 0.22. The company has a current ratio of 1.02, a quick ratio of 0.74 and a debt-to-equity ratio of 0.44.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its earnings results on Tuesday, October 13th. The company reported $2.59 EPS for the quarter, topping the consensus estimate of $2.53 by $0.06. The business had revenue of $25.40 billion during the quarter, compared to the consensus estimate of $25.38 billion. Johnson & Johnson had a return on equity of 31.64% and a net margin of 16.20%. The firm's revenue was up 5.9% compared to the same quarter last year. During the same quarter last year, the company earned $2.80 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. As a group, research analysts predict that Johnson & Johnson will post 11.12 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 8th. Investors of record on Tuesday, November 24th will be issued a dividend of $1.34 per share. This represents a $5.36 dividend on an annualized basis and a dividend yield of 1.9%. The ex-dividend date of this dividend is Tuesday, November 24th. Johnson & Johnson's dividend payout ratio (DPR) is currently 81.21%.

Insiders Place Their Bets

In related news, EVP Timothy Schmid sold 33,597 shares of the company's stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the completion of the sale, the executive vice president directly owned 25,447 shares in the company, valued at $6,991,308.78. This represents a 56.90% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, EVP Elizabeth Forminard sold 13,072 shares of the company's stock in a transaction dated Thursday, November 12th. The shares were sold at an average price of $284.39, for a total transaction of $3,717,546.08. Following the transaction, the executive vice president directly owned 16,994 shares of the company's stock, valued at approximately $4,832,923.66. This trade represents a 43.48% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.16% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. CKW Financial Group increased its holdings in shares of Johnson & Johnson by 0.9% in the 3rd quarter. CKW Financial Group now owns 4,269 shares of the company's stock worth $1,104,000 after acquiring an additional 37 shares during the period. Silver Coast Investments LLC raised its position in shares of Johnson & Johnson by 3.8% during the 2nd quarter. Silver Coast Investments LLC now owns 1,066 shares of the company's stock worth $271,000 after buying an additional 39 shares in the last quarter. Townsend Asset Management Corp NC ADV raised its position in shares of Johnson & Johnson by 0.6% during the 2nd quarter. Townsend Asset Management Corp NC ADV now owns 6,418 shares of the company's stock worth $1,630,000 after buying an additional 39 shares in the last quarter. Triumph Capital Management raised its position in shares of Johnson & Johnson by 1.6% during the 2nd quarter. Triumph Capital Management now owns 2,531 shares of the company's stock worth $643,000 after buying an additional 39 shares in the last quarter. Finally, Kwmg LLC lifted its stake in shares of Johnson & Johnson by 1.7% in the 3rd quarter. Kwmg LLC now owns 2,383 shares of the company's stock worth $631,000 after acquiring an additional 39 shares during the period. 69.55% of the stock is currently owned by institutional investors.

About Johnson & Johnson

(Get Free Report)

Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech. Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care. Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.

Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Johnson & Johnson Right Now?

Before you consider Johnson & Johnson, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.

While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines